EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR

Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.

Authors

Institutions

Publication Details

Journal
Frontiers in Allergy
Published
2025-02-03
DOI
https://doi.org/10.3389/falgy.2024.1531788
Citations
3
Primary Topic
Allergic Rhinitis and Sensitization
Type
article
Field-Weighted Citation Impact
4.87
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR

Peter Smith, Marta Vázquez‐Ortiz, Susana Marinho, Sophie Scheire et al.
3 citations
Frontiers in Allergy
Allergic Rhinitis and Sensitization
4.87
article

EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR

Peter Smith, Marta Vázquez‐Ortiz, Susana Marinho, Sophie Scheire, Anne K. Ellis, Shuaib Nasser, Ralph Mösges, Ruby Pawankar, Wytske J. Fokkens, Luo Zhang, Peter W. Hellings, Susanne Halken, Dermot Ryan, Lars‐Olaf Cardell, D. Price, Michael McDonald, Diego M. Conti, Michael S. Blaiss, Joaquim Mullol, Adam Fox, Livije Kalogjera, Philippe Gevaert, Vibeke Backer, Yun Wang, Ulrich Wahn, G. K. Scadding, Valérie Hox, S. Lau, T. Gilbert Kruz, M. Sosa Kostrábová
article en
3 citations

Abstract

Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.

Frontiers in AllergyVol. 5
Beijing Tongren Hospital (CN), Cliniques Universitaires Saint-Luc (BE), St Thomas' Hospital (GB), Karolinska University Hospital (SE), University Hospital Centre Zagreb (HR), National University of Singapore (SG), University of Cologne (DE), Capital Medical University (CN), University of Aberdeen (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Queen's University (CA), Augusta University (US), Johannesburg Hospital (ZA), Odense University Hospital (DK), Cambridge University Hospitals NHS Foundation Trust (GB), Rigshospitalet (DK), Forum of European National Highway Research Laboratories (BE), Karolinska Institutet (SE), Ghent University (BE), Manchester University NHS Foundation Trust (GB), Royal Brompton Hospital (GB), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Hospital Clínic de Barcelona (ES), Taste and Smell Clinic (US), Observational & Pragmatic Research Institute (SG), Wythenshawe Hospital (GB), Amsterdam University Medical Centers (NL), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), University College London (GB), Imperial College London (GB), Universidad Autónoma de Madrid (ES), Universitat de Barcelona (ES), Charité - Universitätsmedizin Berlin (DE), Nippon Medical School (JP), University of Edinburgh (GB), KU Leuven (BE)
Quality Education
Openalex Percentile: Top 7%
Allergic Rhinitis and Sensitization
4.87
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.